[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  EarningsTime [@Earnings_Time](/creator/twitter/Earnings_Time) on x 7717 followers Created: 2025-07-09 20:18:57 UTC Nurix Therapeutics, $NRIX, Q2-25. Results: 📊 EPS: -$0.52 🟢 💰 Revenue: $44.1M 🟢 📈 Net Loss: $43.5M 🔎 Secured $15M from Sanofi for extending STAT6 collaboration; FDA cleared IND for IRAK4 degrader GS-6791 in Gilead partnership.  XXXXX engagements  **Related Topics** [$15m](/topic/$15m) [$435m](/topic/$435m) [$441m](/topic/$441m) [$nrix](/topic/$nrix) [sanofi](/topic/sanofi) [stocks healthcare](/topic/stocks-healthcare) [Post Link](https://x.com/Earnings_Time/status/1943042211211546757)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
EarningsTime @Earnings_Time on x 7717 followers
Created: 2025-07-09 20:18:57 UTC
Nurix Therapeutics, $NRIX, Q2-25. Results:
📊 EPS: -$0.52 🟢 💰 Revenue: $44.1M 🟢 📈 Net Loss: $43.5M 🔎 Secured $15M from Sanofi for extending STAT6 collaboration; FDA cleared IND for IRAK4 degrader GS-6791 in Gilead partnership.
XXXXX engagements
Related Topics $15m $435m $441m $nrix sanofi stocks healthcare
/post/tweet::1943042211211546757